CME in Minutes: Education in Oncology & Hematology

Please visit answersincme.com/860/102769007-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Aiwu Ruth He, MD, PhD and Mehmet Akce, MD. In this activity, experts in hepatocellular carcinoma (HCC) discuss how the current and emerging clinical evidence for immune checkpoint inhibitor (ICI)–based regimens can elevate personalized care across disease stages, now and into the future. Upon completion of this activity, participants should be better able to: Evaluate the clinical evidence supporting immune checkpoint inhibitor (ICI)–based regimens for the treatment of hepatocellular carcinoma (HCC) across disease settings; Differentiate available ICI-based combination regimens to inform appropriate frontline treatment selection for patients with unresectable HCC; Apply evidence-based strategies to manage immune-related and regimen-specific toxicities associated with ICI-based regimens in patients with HCC; and Design long-term, personalized treatment plans that integrate patient- and disease-related factors into decision-making for HCC.

Please visit answersincme.com/860/IME_2025_00012595-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by John V. Heymach, MD, PhD; and Mark Awad, MD, PhD. In this activity, experts in oncology discuss the role of dual and HER2-selective oral tyrosine kinase inhibitors in patients with HER2-mutated non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Specify how TKIs may address unmet therapeutic needs for diverse patient populations with HER2-mutated NSCLC; Interpret the clinical evidence for approved oral TKIs for patients with HER2-mutated NSCLC; and Assess which patients may be candidates for approved oral HER2-targeting TKIs in the context of the current standard of care.

Please visit answersincme.com/860/2026-MC-001665-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Ajai Chari, MD; Caitlin Costello, MD; and Beth Faiman, PhD, MSN, APN-BC, TCTCN, AOCN, FAAN, FAPO. In this activity, experts in multiple myeloma (MM) discuss the therapeutic rationale, clinical data, and practical integration of subcutaneous anti-CD38 therapies to optimize care for patients with MM. Upon completion of this activity, participants should be better able to: Recognize the rationale for using subcutaneous (SC) formulations of anti-CD38 monoclonal antibodies in patients with multiple myeloma (MM); Assess the clinical profiles of approved and emerging SC formulations of anti-CD38 monoclonal antibodies in patients with MM; and Outline evidence-based, patient-centered strategies for optimizing outcomes with SC formulations of anti-CD38 monoclonal antibodies in patients with MM.

Please visit answersincme.com/860/101385133-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Peter A. Fasching, MD; Michael Gnant, MD, FACS; and Cristina Saura Manich, MD, PhD. In this activity, experts in breast cancer discuss new evidence in neoadjuvant and adjuvant care of early disease. Upon completion of this activity, participants should be better able to: Describe multidisciplinary viewpoints on the role that HER2-directed ADCs may play in the (neo)adjuvant setting for HER2-positive early-stage breast cancer; Evaluate evidence for the (neo)adjuvant use of HER2-directed ADCs in the multidisciplinary management of HER2-positive early-stage breast cancer; and Formulate evidence-based multidisciplinary strategies to optimally incorporate (neo)adjuvant HER2-directed ADCs into the treatment paradigm for HER2-positive early-stage breast cancer.

Please visit answersincme.com/PNQ860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Rachel Goodwin, MSc, MD, FRCPC; and Vincent Tam, MD. In this activity, experts in colorectal cancer and biliary tract cancer discuss first-line immunotherapy considerations. Upon completion of this activity, participants should be better able to: Evaluate the clinical profiles of first-line immunotherapy-based regimens for the treatment of patients with advanced colorectal cancer (CRC); Formulate strategies to individualize first-line immunotherapy-based regimens for patients with advanced CRC; Describe the clinical evidence on first-line immunotherapy-based regimens for patients with advanced biliary tract cancer (BTC); and Apply patient-, drug-, and disease-specific considerations to optimize first-line immunotherapy-based regimens for patients with advanced BTC.